FinnCap reaffirmed their corporate rating on shares of Avacta Group (LON:AVCT) in a report published on Monday morning. FinnCap currently has a GBX 200 ($2.71) price target on the biotechnology company’s stock.

Avacta Group (LON:AVCT) opened at GBX 66.50 ($0.90) on Monday. The firm has a market cap of $45.90 and a price-to-earnings ratio of -738.89. Avacta Group has a 52-week low of GBX 60 ($0.81) and a 52-week high of GBX 98 ($1.33).

TRADEMARK VIOLATION NOTICE: “Avacta Group (AVCT) Given “Corporate” Rating at FinnCap” was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another publication, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be viewed at

Avacta Group Company Profile

Avacta Group plc is a biotechnology company. Avacta’s focus is on its proprietary Affimer technology which is an engineered alternative to antibodies that has application in Life Sciences for diagnostics, therapeutics and general research and development. Affimer technology has been designed to address performance limitations of antibodies.

Receive News & Ratings for Avacta Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avacta Group and related companies with's FREE daily email newsletter.